Key result
A 62-year-old male with extensive-stage non-small-cell lung carcinoma and massive pericardial effusion responded well to a multidisciplinary treatment plan including chemotherapy and immunotherapy.
Case Report (n=1)
This case report emphasizes the need for vigilant cardiovascular monitoring in patients receiving immunotherapy for lung cancer due to the risk of severe immune-related adverse events like pericardial effusion.
Case reports of cytology-proven malignant pericardial effusion support diagnostic evaluation; this single observation leaves open questions on multimodal therapy outcomes.
This case report presents a late middle-aged man with a right infra-hilar lung mass and pericardial effusion (PE). The patient was diagnosed with metastatic small-cell lung carcinoma, with metastases to the liver, pancreas, and cerebellum. The pericardial fluid cytology confirmed the presence of malignant cells most compatible with non-small-cell carcinoma. The patient received carbo/etoposide chemotherapy, and his treatment plan included adding atezolizumab and radiation therapy. Despite the excellent efficacy of immunotherapy, immune-related adverse events (IRAEs), including cardiac toxicity, were noted in some patients. PE related to immune checkpoint inhibitor (ICI) use is rare but potentially severe. This case highlights the importance of vigilant monitoring for cardiovascular symptoms during immunotherapy and the significance of pericardial fluid analysis in diagnosing malignant pericardial disease. Prompt diagnosis and appropriate treatment can lead to improved patient outcomes in cases of lung cancer-associated cardiac complications.
No takes yet. Share an insight, caveat, or question.
Hussain et al. (2023) conducted a case report in Non-small-cell lung carcinoma with massive pericardial effusion and cardiac tamponade (n=1). Carbo/etoposide chemotherapy, atezolizumab immunotherapy, and radiation therapy was evaluated. A 62-year-old male with extensive-stage non-small-cell lung carcinoma and massive pericardial effusion responded well to a multidisciplinary treatment plan including chemotherapy and immunotherapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: